Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 16, 2022; 10(11): 3478-3484
Published online Apr 16, 2022. doi: 10.12998/wjcc.v10.i11.3478
Published online Apr 16, 2022. doi: 10.12998/wjcc.v10.i11.3478
Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer: A case report
Kai-Kai Huang, Shan-Shan Han, Li-Ya He, Lin-Lin Yang, Bao-Ying Liang, Qing-Yu Zhen, Zi-Bo Zhu, Hong-Yi Li, Ying Lin, Department of Dermatology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, China
Cai-Yun Zhang, Department of Dermatology, the Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, China
Ying Lin, Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases, Guangzhou 510120, Guangdong Province, China
Author contributions: Huang KK, Han SS, and Zhang CY contributed to the treatment, literature search; Huang KK, He LY and Zhen QY contributed to manuscript writing; Lin Y, Yang LL, and Liang BY contributed to the treatment and manuscript revision; Zhu ZB and Li HY provided comments to this literature; informed consent was conducted by Huang KK; all authors have read and approved the final manuscript.
Supported by Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases , No. 2018B030322012 .
Informed consent statement: Consent was obtained from the relatives of the patient for publication of this report and any accompanying results.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ying Lin, MD, Chief Physician, Department of Dermatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 111 Dade Road, Yuexiu District, Guangzhou 510120, Guangdong Province, China. lin19791226@gzucm.edu.cn
Received: July 25, 2021
Peer-review started: July 25, 2021
First decision: December 27, 2021
Revised: January 15, 2022
Accepted: February 27, 2022
Article in press: February 27, 2022
Published online: April 16, 2022
Peer-review started: July 25, 2021
First decision: December 27, 2021
Revised: January 15, 2022
Accepted: February 27, 2022
Article in press: February 27, 2022
Published online: April 16, 2022
Core Tip
Core Tip: Both programmed cell death-1 (PD-1) inhibitors and lenvatinib, which exhibit a synergistic effect, are promising drugs for tumor treatment. However, we encountered a patient who presented with erythema, blisters and erosions on the face, neck, trunk and limbs 1 wk after combination therapy with lenvatinib and toripalimab, a PD-1 inhibitor. Skin biopsy was performed, and the diagnosis was confirmed as toxic epidermal necrolysis (TEN). We are the first group to report the occurrence of TEN, a grade 4 toxicity, after this combination therapy. Full-dose and long-term corticosteroids were administered, and the rashes gradually faded.